Study of Ambrisentan in Participants With Pulmonary Hypertension
Status:
Completed
Trial end date:
2019-09-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to monitor the long-term safety of ambrisentan in
adult participants with pulmonary hypertension. The available ambrisentan doses for this
study are 2.5, 5, or 10 mg administered orally once daily. Investigators will be able to
adjust ambrisentan dose as clinically indicated. A minimum of 4 weeks between dose
adjustments is required. Participants receiving other therapies for pulmonary hypertension
that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in
this study and continue to receive such therapies. Participants enrolled in this study will
receive treatment with ambrisentan until such time as the investigator or participant chooses
to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor
stops the study.